The ANGIE project represents a significant step beyond the current state of the art in targeted drug delivery, micro-robotics, and interventional medicine. Unlike existing systemic delivery approaches or catheter-based interventions with limited reach and specificity, ANGIE introduces a paradigm-shifting platform: fully biodegradable, magnetically steerable microcapsules guided by external electromagnetic fields to precisely deliver drugs in deep and tortuous vasculature.
Key innovations include:
• A clinically compatible electromagnetic navigation system (eMNS) with real-time control over both position and orientation of microdevices inside flowing blood.
• Biodegradable, drug-loaded capsules with tunable release profiles and visibility under fluoroscopy.
• Robust control algorithms and tracking systems, enabling automated navigation through bifurcations and complex vascular geometries.
• Integration with clinical tools, such as custom-designed catheters and angiographic imaging, allowing seamless translation to clinical workflows.
By the end of the project, ANGIE has already demonstrated proof-of-concept in benchtop, ex vivo, and in vivo environments.
The expected impacts are multi-dimensional:
• Clinical impact: ANGIE enables site-specific delivery of thrombolytic or cytotoxic agents, potentially reducing systemic side effects, improving therapeutic efficacy, and enabling intervention in previously inaccessible regions (e.g. distal neurovascular clots).
• Economic impact: By decreasing reliance on systemic therapies and surgical interventions, ANGIE can reduce hospitalization times, treatment costs, and complications—yielding savings for healthcare systems.
• Technological impact: The project has set new benchmarks in microrobotic design, navigation, and drug delivery systems, which will catalyze innovation in both academia and industry.
• Societal impact: ANGIE addresses major health burdens such as ischemic stroke and cancer, offering precision, minimally invasive therapeutic options that improve quality of life and long-term outcomes.
Socio-economically, ANGIE fosters high-tech job creation, promotes interdisciplinary collaboration, and strengthens Europe’s leadership in medical robotics and nanomedicine. By forming startups, engaging with public stakeholders, and training early-stage innovators, ANGIE has already initiated a ripple effect in research, industry, and public awareness that will persist beyond the project’s lifetime.
